{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:30:01Z","timestamp":1774589401159,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijcard.2024.132914","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:03:11Z","timestamp":1734652991000},"page":"132914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cardiorenal outcomes associated with sodium-glucose co-transporter-2 inhibitors in chronic kidney disease stage 5 (CKD V): A propensity score-matched analysis"],"prefix":"10.1016","volume":"422","author":[{"given":"Anderson","family":"Anuforo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayorinde","family":"Soipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toluwalase","family":"Awoyemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olanrewaju","family":"Adeniran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Somerville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nnokam","family":"Nnekachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin","family":"Chilaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth","family":"Yandrapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.132914_bb0005","doi-asserted-by":"crossref","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl. (2011). 2022;12(1):7-11. doi:https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003.","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"10.1016\/j.ijcard.2024.132914_bb0010","author":"Chronic Kidney Disease in the United States"},{"key":"10.1016\/j.ijcard.2024.132914_bb0015","doi-asserted-by":"crossref","unstructured":"Major RW, Cheng MRI, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. Reboldi G, ed. PLoS ONE. 2018;13(3):e0192895. doi:10.1371\/journal.pone.0192895.","DOI":"10.1371\/journal.pone.0192895"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132914_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1573403X14666180711124825","article-title":"Chronic kidney disease and cardiovascular disease: is there any relationship?","volume":"15","author":"Vallianou","year":"2018","journal-title":"Curr. Cardiol. Rev."},{"issue":"12","key":"10.1016\/j.ijcard.2024.132914_bb0025","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ijcard.2024.132914_bb0030","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ijcard.2024.132914_bb0035","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132914_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1139\/cjpp-2021-0399","article-title":"Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis","volume":"100","author":"Gronda","year":"2022","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132914_bb0045","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","author":"Herrington","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"issue":"24","key":"10.1016\/j.ijcard.2024.132914_bb0050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132914_bb0055","author":"FDA"},{"key":"10.1016\/j.ijcard.2024.132914_bb0060","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for dialysis and cardiovascular disease in patients with stage 5 chronic kidney disease","volume":"30","author":"Yen","year":"2024","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132914_bb0065","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.mayocp.2024.05.007","article-title":"Empagliflozin and cardiovascular outcomes across urine albumin to creatinine ratio categories: a systematic review and meta-analysis","volume":"99","author":"Abdelaziz","year":"2024","journal-title":"Mayo Clin. Proc."},{"issue":"19","key":"10.1016\/j.ijcard.2024.132914_bb0070","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.jacc.2023.08.026","article-title":"Dapagliflozin in patients with heart\u00a0failure and deterioration in renal\u00a0function","volume":"82","author":"Chatur","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132914_bb0075","unstructured":"History of Changes for Study: NCT05179668 2024. Accessed November 21, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/history\/NCT05179668?V_3=View."},{"key":"10.1016\/j.ijcard.2024.132914_bb0080","unstructured":"Publication Guidelines \u2013 TriNetX 2024. Accessed October 30, 2023. https:\/\/trinetx.com\/real-world-resources\/publications\/trinetx-publication-guidelines\/."},{"issue":"13","key":"10.1016\/j.ijcard.2024.132914_bb0085","doi-asserted-by":"crossref","first-page":"F3","DOI":"10.1097\/QAD.0000000000002666","article-title":"Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study","volume":"34","author":"Hadi","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.ijcard.2024.132914_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106606","article-title":"Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: a multicenter retrospective research network study","volume":"188","author":"Hadi","year":"2021","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132914_bb0095","doi-asserted-by":"crossref","first-page":"832","DOI":"10.21037\/tau-22-631","article-title":"A global, propensity-score matched analysis of patients receiving artificial urinary sphincters and the risk of complications, infections, and re-interventions","volume":"12","author":"Prebay","year":"2023","journal-title":"Transl Androl. Urol."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132914_bb0100","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132914_bb0105","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00208.2003","article-title":"Kidney function in early diabetes: the tubular hypothesis of glomerular filtration","volume":"286","author":"Thomson","year":"2004","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"12","key":"10.1016\/j.ijcard.2024.132914_bb0110","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1681\/ASN.2007121326","article-title":"Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis","volume":"19","author":"Thomson","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132914_bb0115","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1681\/ASN.2007060721","article-title":"Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury","volume":"19","author":"Faulhaber-Walter","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132914_bb0120","article-title":"Correction: dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury","volume":"11","author":"Chang","year":"2016","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.ijcard.2024.132914_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. Yagihashi S, ed","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.ijcard.2024.132914_bb0130","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.ijcard.2024.132914_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132914_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031805","article-title":"Comparison of effectiveness among different sodium-glucose cotransoporter-2 inhibitors according to underlying conditions: a network meta-analysis of randomized controlled trials","volume":"13","author":"Kani","year":"2024","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132914_bb0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0002-9343(02)01054-9","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"113","author":"Foxman","year":"2002","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132914_bb0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.22141\/2307-1257.11.1.2022.356","article-title":"UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease","volume":"11","author":"Authors","year":"2022","journal-title":"Kidneys"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324015365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324015365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T19:34:22Z","timestamp":1738611262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324015365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"alternative-id":["S0167527324015365"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132914","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiorenal outcomes associated with sodium-glucose co-transporter-2 inhibitors in chronic kidney disease stage 5 (CKD V): A propensity score-matched analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132914"}}